Media

Manchester and London, UK, 19 January, 2015 – C4X Discovery Holdings plc (C4XD), a leader in rational drug discovery and design, announced today that it has entered into a research agreement with Evotec. Under the agreement C4XD's proprietary NMR-based technology and conformational design expertise will combine with Evotec's extensive biology and chemistry expertise. The aim is to develop several series of Orexin-1 selective inhibitors, building on elements of the substantial work which C4XD has previously conducted in the field of specific Orexin inhibitors.

Manchester and London, UK, 18 December, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, announced today that it has extended its research collaboration agreement with Evotec, under which C4XD's proprietary NMR-based technology and conformational design expertise is applied across a number of Evotec's pre-clinical therapeutic projects to enhance lead discovery and hit identification.

Manchester and London, UK, 23 October, 2014 – C4X Discovery (C4XD), a drug development company with a leading technology for rational drug discovery and design, announced that Admission and trading of its Ordinary Shares commences today on the AIM market of the London Stock Exchange ('AIM').

Manchester and London, UK, 23 September, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, today announced further positive data from its Orexin-1 programme to treat stress-related addictive disorders.

Manchester and London, UK, 8 September, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, announced today that it has signed a research collaboration agreement under which C4XD's proprietary NMR-based technology will be applied across a number of Evotec's pre-clinical therapeutic projects to enhance lead discovery and hit identification.

Manchester and London, UK, 4 September, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, today announced positive initial data from its Orexin-1 programme to treat stress-related addictive disorders, and the filing of a related patent.

Manchester and London, UK, 26 August, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, announced today that it has signed a research collaboration agreement with Takeda Cambridge Limited ("TCB"), a UK subsidiary of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. Under the agreement, C4XD's proprietary NMR-based technology will be applied across a number of TCB's therapeutic projects to enhance lead discovery and hit identification.

Manchester and London, UK, 4 July, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, today announced that its patent relating to a new method for determining the three-dimensional structures of dynamic molecules has been granted in Japan.